Trial reportThe New England journal of medicine2021
SARS-CoV-2 Neutralization with BNT162b2 Vaccine Dose 3.
Trial report in The New England journal of medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 254 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
254 citing papers in PubMed.
- Trial
- Immunogenicity of BNT162b2 as a first booster after a ChAdOx1 primary series in a Thai geriatric population living with frailty.The journal of nutrition, health & aging · 2024Trial
- Safety and immunogenicity of SARS-CoV-2 self-amplifying RNA vaccine expressing an anchored RBD: A randomized, observer-blind phase 1 study.Cell reports. Medicine · 2023Trial
- Evaluation of BNT162b2 Covid-19 Vaccine in Children Younger than 5 Years of Age.The New England journal of medicine · 2023Trial
- Immunogenicity of a Third Dose of BNT162b2 to Ancestral Severe Acute Respiratory Syndrome Coronavirus 2 and the Omicron Variant in Adults Who Received 2 Doses of Inactivated Vaccine.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2023Trial
- Titers and breadth of neutralizing antibodies against SARS-CoV-2 variants after heterologous booster vaccination in health care workers primed with two doses of ChAdOx1 nCov-19: A single-blinded, randomized clinical trial.Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology · 2022Trial
- Neutralization of Omicron sublineages and Deltacron SARS-CoV-2 by three doses of BNT162b2 vaccine or BA.1 infection.Emerging microbes & infections · 2022Trial
- A fourth dose of the inactivated SARS-CoV-2 vaccine redistributes humoral immunity to the N-terminal domain.Nature communications · 2022Trial
- Immune Persistence and Safety After SARS-CoV-2 BNT162b1 mRNA Vaccination in Chinese Adults: A Randomized, Placebo-Controlled, Double-Blind Phase 1 Trial.Advances in therapy · 2022Trial
- Trial
- Immunogenicity and safety of NVSI-06-07 as a heterologous booster after priming with BBIBP-CorV: a phase 2 trial.Signal transduction and targeted therapy · 2022Trial
- Six-month follow-up of a booster dose of CoronaVac in two single-centre phase 2 clinical trials.Nature communications · 2022Trial
- Safety and Efficacy of a Third Dose of BNT162b2 Covid-19 Vaccine.The New England journal of medicine · 2022Trial
- Immunogenicity and safety of a third dose of CoronaVac, and immune persistence of a two-dose schedule, in healthy adults: interim results from two single-centre, double-blind, randomised, placebo-controlled phase 2 clinical trials.The Lancet. Infectious diseases · 2022Trial
- Safety and immunogenicity of a high-dose quadrivalent influenza vaccine administered concomitantly with a third dose of the mRNA-1273 SARS-CoV-2 vaccine in adults aged ≥65 years: a phase 2, randomised, open-label study.The Lancet. Respiratory medicine · 2022Trial
- Longer-term response to SARS-CoV-2 vaccination after allogeneic blood stem cell transplantation.Journal of cancer research and clinical oncology · 2026Article
- The magnitude and durability of neutralizing antibody responses to human papillomavirus vaccine do not depend on DNA sensing pathways.Journal of virology · 2026Article
- Investigation of the administration technique and side effects of COVID-19 vaccines: a descriptive and cross-sectional study.Scientific reports · 2026Article
- Establishing long-lasting vaccine immunity: insights from mRNA and adjuvanted protein platforms.NPJ vaccines · 2025Review
- Article
194 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
24 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.